(Q36917254)

17 August 2017

1 reference

title

Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? (English)

1 reference

17 August 2017

1 reference

Katherine L O'Brien

1

0 references

David Goldblatt

object named as

David Goldblatt

series ordinal

3

1 reference

ORCID Public Data File 2021

author name string

Michael Hochman

series ordinal

2

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Lancet Infectious Diseases

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

597-606

1 reference

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immunogenicity and Safety of Measles-Mumps-Rubella, Varicella and Haemophilus influenzae Type b Vaccines Administered Concurrently With a Fourth Dose of Heptavalent Pneumococcal Conjugate Vaccine Compared With the Vaccines Administered Without Heptav

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Antibody responses after immunization with polyvalent pneumococcal vaccine containing 10, 25, or 50 micrograms of 14 polysaccharide types per dose

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston. The Greater Boston Collaborative Otitis Media Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conju

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Dietary fiber and weight gain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Kinetics of Antibody Production to Group A and Group C Meningococcal Polysaccharide Vaccines Administered during the First Six Years of Life: Prospects for Routine Immunization of Infants and Children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immune Response of Human Infants to Polysaccharide Vaccines of Groups A and C Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Safety of revaccination with pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Vaccination and Revaccination with Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and Infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Antibody to Capsular Polysaccharides of Streptococcus pneumoniae: Prevalence, Persistence, and Response to Revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immunogenicity of pneumococcal revaccination in patients with chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Pneumococcal revaccination of splenectomized children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Clinical Studies of Pneumococcal Vaccines in Infants. I. Reactogenicity and Immunogenicity of Two Polyvalent Polysaccharide Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Pneumococcal vaccine in normal children. Primary and secondary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Polysaccharide processing and presentation by the MHCII pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Circulating polyribophosphate in Hemophilus influenzae, type b meningitis. Correlation with clinical course and antibody response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immunological paralysis to pneumococcal polysaccharide in man

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Pneumococcal conjugate vaccine for acute otitis media--yes or no?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Regulation of antibody responses via antibodies, complement, and Fc receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein- and polysaccharide-specific immunoglobulin isotype responses in vivo through distinct mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

Pneumococcal polysaccharides interact with human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

T-cell modulation of the antibody response to bacterial polysaccharide antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

T-cell modulation of the murine antibody response to Neisseria meningitidis group A capsular polysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970210-4

7 January 2021

10.1016/S1473-3099(07)70210-4

Identifiers

DOI

1 reference

17 August 2017

1 reference